abstract |
The present invention relates to new selective allosteric modulators of the alpha5 subunit of GABA A receptors which have been deuterated for the purpose of improving the medical properties thereof, by prolonging their half-lives, which makes them useful as fast-acting pharmaceutical treatments for disorders related to depression. |